Barclays PLC Reduces Holdings in Kenvue Inc. (NYSE:KVUE)

Barclays PLC reduced its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 3.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,299,130 shares of the company's stock after selling 198,290 shares during the quarter. Barclays PLC owned approximately 0.28% of Kenvue worth $122,569,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Huntington National Bank boosted its holdings in shares of Kenvue by 26.5% during the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company's stock valued at $96,000 after buying an additional 871 shares in the last quarter. ING Groep NV boosted its holdings in shares of Kenvue by 23.6% during the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company's stock valued at $82,727,000 after buying an additional 681,954 shares in the last quarter. Kennon Green & Company LLC boosted its holdings in shares of Kenvue by 140.7% during the 2nd quarter. Kennon Green & Company LLC now owns 159,106 shares of the company's stock valued at $2,893,000 after buying an additional 93,008 shares in the last quarter. Lorne Steinberg Wealth Management Inc. boosted its holdings in shares of Kenvue by 59.0% during the 2nd quarter. Lorne Steinberg Wealth Management Inc. now owns 154,690 shares of the company's stock valued at $2,812,000 after buying an additional 57,375 shares in the last quarter. Finally, Crestwood Advisors Group LLC boosted its holdings in shares of Kenvue by 14.8% during the 2nd quarter. Crestwood Advisors Group LLC now owns 1,537,348 shares of the company's stock valued at $27,950,000 after buying an additional 198,607 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

KVUE traded down $0.51 during trading on Wednesday, reaching $22.23. 9,433,236 shares of the company traded hands, compared to its average volume of 17,686,359. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The firm has a fifty day simple moving average of $22.95 and a 200 day simple moving average of $21.16. The company has a market cap of $42.62 billion, a P/E ratio of 40.42, a PEG ratio of 2.07 and a beta of 1.37.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company's quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.31 EPS. On average, equities analysts forecast that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.69%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue's payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on KVUE. Jefferies Financial Group began coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a "buy" rating and a $27.00 price target on the stock. Piper Sandler upped their price target on shares of Kenvue from $20.00 to $21.00 and gave the stock a "neutral" rating in a research note on Monday, September 23rd. Royal Bank of Canada upgraded shares of Kenvue from a "hold" rating to a "moderate buy" rating in a research note on Monday. Bank of America upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, October 22nd. Finally, JPMorgan Chase & Co. upped their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and a consensus price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.